Deltagen Gets Nasdaq Deficiency Letter; R&D Cuts Loom, But Core Tech Immune | GenomeWeb

NEW YORK, Jan. 2 - Deltagen has until March 19 to pull its share price above $1 or risk being delisted from the Nasdaq, a company spokeswoman told GenomeWeb earlier this week.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.